The stock of Flexion Therapeutics Inc (NASDAQ:FLXN) is a huge mover today! About 113,186 shares traded hands. Flexion Therapeutics Inc (NASDAQ:FLXN) has risen 103.69% since March 8, 2016 and is uptrending. It has outperformed by 94.37% the S&P500.
The move comes after 7 months negative chart setup for the $533.24M company. It was reported on Oct, 11 by Barchart.com. We have $17.99 PT which if reached, will make NASDAQ:FLXN worth $26.66M less.
Analysts await Flexion Therapeutics Inc (NASDAQ:FLXN) to report earnings on November, 14. They expect $-0.67 EPS, down 28.85% or $0.15 from last year’s $-0.52 per share. After $-0.63 actual EPS reported by Flexion Therapeutics Inc for the previous quarter, Wall Street now forecasts 6.35% negative EPS growth.
Flexion Therapeutics Inc (NASDAQ:FLXN) Ratings Coverage
Out of 7 analysts covering Flexion Therapeutics (NASDAQ:FLXN), 7 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Flexion Therapeutics has been the topic of 7 analyst reports since July 31, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by Lake Street given on Thursday, July 21. The stock of Flexion Therapeutics Inc (NASDAQ:FLXN) earned “Buy” rating by Cantor Fitzgerald on Wednesday, November 4. The stock of Flexion Therapeutics Inc (NASDAQ:FLXN) has “Outperform” rating given on Tuesday, May 3 by Wells Fargo. The stock of Flexion Therapeutics Inc (NASDAQ:FLXN) earned “Outperform” rating by BMO Capital Markets on Wednesday, June 29. Needham maintained Flexion Therapeutics Inc (NASDAQ:FLXN) rating on Wednesday, September 9. Needham has “Buy” rating and $28.0 price target.
According to Zacks Investment Research, “Flexion Therapeutics, Inc. is a specialty pharmaceutical company. It is focused on the development and commercialization of injectable pain therapies. The Company is targeting anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It operates in the United States. The Company’s product candidate, FX006, is an injectable intra-articular, meaning in the joint, sustained-release treatment for patients with moderate to severe OA pain. It is developing two additional product candidates, FX007 for post-operative pain and FX005 to treat end-stage OA patients. Flexion Therapeutics, Inc. is headquartered in Burlington, Massachusetts.”
Insitutional Activity: The institutional sentiment increased to 2.85 in Q2 2016. Its up 1.20, from 1.65 in 2016Q1. The ratio is positive, as 9 funds sold all Flexion Therapeutics Inc shares owned while 11 reduced positions. 21 funds bought stakes while 36 increased positions. They now own 18.68 million shares or 38.37% more from 13.50 million shares in 2016Q1.
Moreover, Northern Trust has 0% invested in Flexion Therapeutics Inc (NASDAQ:FLXN) for 237,786 shares. Blackrock Advsrs Ltd Liability accumulated 0% or 26,726 shares. Citigroup accumulated 0% or 3,254 shares. Grt Cap Prtn Limited Liability Com has invested 0.16% of its portfolio in Flexion Therapeutics Inc (NASDAQ:FLXN). Gam Hldg Ag reported 261,000 shares or 0.06% of all its holdings. Macquarie Grp Inc Inc Limited reported 78,307 shares or 0% of all its holdings. Blackrock Institutional Tru Na accumulated 0% or 300,406 shares. Driehaus Mngmt Limited Liability reported 891,274 shares or 0.48% of all its holdings. Financial Bank Of Montreal Can holds 0% of its portfolio in Flexion Therapeutics Inc (NASDAQ:FLXN) for 13,611 shares. Adage Capital Partners Group Ltd Llc holds 0% of its portfolio in Flexion Therapeutics Inc (NASDAQ:FLXN) for 76,000 shares. Teachers holds 29,707 shares or 0% of its portfolio. Wall Street Associates holds 113,400 shares or 0.68% of its portfolio. Rhumbline Advisers reported 17,073 shares or 0% of all its holdings. Geode Mgmt Limited Liability Co accumulated 0% or 145,396 shares. Bnp Paribas Arbitrage reported 734 shares or 0% of all its holdings.
Insider Transactions: Since May 16, 2016, the stock had 15 insider purchases, and 0 insider sales for $30.21 million net activity. Another trade for 714,285 shares valued at $10.00M was made by COLELLA SAMUEL D on Wednesday, June 8. 2,000 shares were bought by Clayman Michael D., worth $20,810. MERRIFIELD C ANN bought $13,387 worth of stock. Shares for $8,500 were bought by Bodick Neil on Thursday, May 19. The insider Versant Ventures III – LLC bought 714,285 shares worth $10.00M. $22,972 worth of Flexion Therapeutics Inc (NASDAQ:FLXN) was bought by DRISCOLL FREDERICK W. 714,285 shares with value of $10.00 million were bought by LUBASH BARBARA N on Wednesday, June 8.
More important recent Flexion Therapeutics Inc (NASDAQ:FLXN) news were published by: Globenewswire.com which released: “Flexion Therapeutics Announces Two Key Corporate Appointments” on September 12, 2016, also Marketwatch.com published article titled: “/quotes/zigman/3870025/realtime”, Seekingalpha.com published: “Flexion Therapeutics: Insider Buying Signals Attractive Opportunity” on July 08, 2016. More interesting news about Flexion Therapeutics Inc (NASDAQ:FLXN) was released by: Globenewswire.com and their article: “Flexion Therapeutics Announces Appointment of Mark Stejbach to its Board of …” with publication date: September 14, 2016.
FLXN Company Profile
Flexion Therapeutics, Inc., incorporated on November 5, 2007, is a specialty pharmaceutical company. The Firm is focused on the development and commercialization of therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis and post-operative pain. The Company’s portfolio of product candidates addresses the OA pain treatment spectrum, from moderate to severe pain. The Company’s lead product candidate, Zilretta (also known as FX006), is a late-stage, injectable, sustained-release, intra-articular (IA) steroid for patients with moderate to severe OA pain. The Company’s other product candidates include FX007 for post-operative pain and FX005 for the treatment of end-stage OA patients. The Firm has not generated any revenue.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.